Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · IEX Real-Time Price · USD
962.49
-3.81 (-0.39%)
At close: Mar 28, 2024, 4:00 PM
962.45
-0.04 (0.00%)
After-hours: Mar 28, 2024, 7:26 PM EDT
-0.39%
Market Cap 105.41B
Revenue (ttm) 13.12B
Net Income (ttm) 3.95B
Shares Out 107.94M
EPS (ttm) 34.77
PE Ratio 27.68
Forward PE 21.08
Dividend n/a
Ex-Dividend Date n/a
Volume 446,659
Open 970.38
Previous Close 966.30
Day's Range 959.18 - 970.79
52-Week Range 684.81 - 998.33
Beta 0.11
Analysts Buy
Price Target 965.52 (+0.31%)
Earnings Date May 2, 2024

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 2, 1991
Employees 13,450
Stock Exchange NASDAQ
Ticker Symbol REGN
Full Company Profile

Financial Performance

In 2023, REGN's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $965.52, which is an increase of 0.31% from the latest price.

Price Target
$965.52
(0.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

US FDA declines to approve Regeneron's blood cancer therapy

Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined to approve its blood cancer therapy for two most common subtypes of non-Hodgkin lymphoma due to an issue related to enrollment of its...

4 days ago - Reuters

Regeneron Provides Update on Biologics License Application for Odronextamab

TARRYTOWN, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters...

4 days ago - GlobeNewsWire

US appeals court revives Regeneron's antitrust lawsuit against Novartis

A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders inclu...

Other symbols: NVS
10 days ago - Reuters

Calls of the Day: Regeneron, Thermo Fisher, Darden Restaurants and Nucor

The Investment Committee debate the latest calls of the day on a number of stocks.

Other symbols: DRINUETMO
15 days ago - CNBC Television

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

$250,000 top award goes to Achyuta Rajaram in the nation's oldest and most prestigious Science, Technology, Engineering and Math  (STEM) competition for high school seniors TARRYTOWN, N.Y. and WASHING...

16 days ago - PRNewsWire

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) Approval extends treatment of Praluent to children aged 8 and older with hete...

18 days ago - GlobeNewsWire

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA ® (aflibercept) Injection 2 mg with fixed 8-week dosing in...

21 days ago - GlobeNewsWire

GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta

ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma announces an exclusive distribution agreement with Regeneron Pharmaceuticals to commercialize cemiplimab in Greece, Cyprus and Malta.

4 weeks ago - Business Wire

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

Priority Review granted based on positive results from two Phase 3 trials; i f approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in m...

5 weeks ago - GlobeNewsWire

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Dupixent ® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Other symbols: SNY
5 weeks ago - GlobeNewsWire

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

TARRYTOWN, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the ...

5 weeks ago - GlobeNewsWire

Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to pl...

Other symbols: SNY
6 weeks ago - GlobeNewsWire

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dup...

6 weeks ago - GlobeNewsWire

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

7 weeks ago - GlobeNewsWire

Regeneron beats quarterly revenue estimates

Drug maker Regeneron beat fourth-quarter revenue estimates on Friday.

2 months ago - Reuters

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2023 and provided a business up...

2 months ago - GlobeNewsWire

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authori...

2 months ago - GlobeNewsWire

2seventy bio to sell experimental cell therapies to Regeneron

Cancer treatment maker 2seventy bio will sell all its experimental cell therapies to Regeneron Pharmaceuticals for an upfront payment of $5 million and focus on its sole approved product Abecma, the t...

Other symbols: TSVT
2 months ago - Reuters

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

Regeneron to assume full development and commercialization rights for 2seventy bio's preclinical and clinical stage cell therapy pipeline Regeneron to assume full development and commercialization rig...

2 months ago - GlobeNewsWire

US FDA approves Dupixent to treat younger kids with esophageal condition

The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg, t...

Other symbols: SNY
2 months ago - Reuters

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proporti...

Other symbols: SNY
2 months ago - GlobeNewsWire

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo

2 months ago - GlobeNewsWire

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) TARRYTOWN, N.Y. and WASHINGTON , Jan. 24, 2024 /PRNewswire...

2 months ago - PRNewsWire

10 Healthcare Stocks That Are Heating Up

The sector has seen one of the best starts to the year in decades, Goldman says.

2 months ago - Barrons

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

Data included from first and only Phase 3 trial specifically evaluating a biologic in this difficult-to-treat population Phase 3 trial showed more than twice as many patients treated with Dupixent ach...

2 months ago - GlobeNewsWire